Related references
Note: Only part of the references are listed.Feasibility and Safety of ALVAC-HIV vCP1521 Vaccine in HIV-Exposed Infants in Uganda: Results From the First HIV Vaccine Trial in Infants in Africa
Kenneth Kintu et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)
Lindsey R. Baden et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)
Dan H. Barouch et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E
Supachai Rerks-Ngarm et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
Stephen R. Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors
Pablo Penaloza-MacMaster et al.
JOURNAL OF VIROLOGY (2013)
Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype C gag Vaccine in Healthy HIV-1-Uninfected Adults
M. Wecker et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients
Alexandre Harari et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load
Yaowaluck Roshorm et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer
Robert J. Amato et al.
FUTURE ONCOLOGY (2012)
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study)
Ann Duerr et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
Geraldine A. O'Hara et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes
Matthieu Perreau et al.
JOURNAL OF VIROLOGY (2012)
Adenovirus Serotype 26 Utilizes CD46 as a Primary Cellular Receptor and Only Transiently Activates T Lymphocytes following Vaccination of Rhesus Monkeys
Hualin Li et al.
JOURNAL OF VIROLOGY (2012)
Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys
Jeffrey E. Teigler et al.
JOURNAL OF VIROLOGY (2012)
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland et al.
NATURE (2012)
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Dan H. Barouch et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
Silvia Ratto-Kim et al.
PLOS ONE (2012)
A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
Matthew D. J. Dicks et al.
PLOS ONE (2012)
A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults
Michael C. Keefer et al.
PLOS ONE (2012)
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
Stefano Colloca et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses
Stephen R. Walsh et al.
VACCINE (2012)
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors
Stephen R. Walsh et al.
EXPERT REVIEW OF VACCINES (2011)
An Ad5-Vectored HIV-1 Vaccine Elicits Cell-mediated Immunity but does not Affect Disease Progression in HIV-1-infected Male Subjects: Results From a Randomized Placebo-Controlled Trial (The Step Study)
D. W. Fitzgerald et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Paul A. Goepfert et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2h study
Glenda E. Gray et al.
LANCET INFECTIOUS DISEASES (2011)
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
Norman L. Letvin et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
Dan H. Barouch et al.
VACCINE (2011)
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
Michael C. Keefer et al.
VACCINE (2011)
Safety and Immunogenicity of Modified Vaccinia Ankara (ACAM3000): Effect of Dose and Route of Administration
Marissa B. Wilck et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae
H. Chen et al.
JOURNAL OF VIROLOGY (2010)
Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
Jeffrey R. Currier et al.
PLOS ONE (2010)
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
T. Christopher Mast et al.
VACCINE (2010)
Novel adenovirus vector-based vaccines for HIV-1
Dan H. Barouch
CURRENT OPINION IN HIV AND AIDS (2010)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors
Sampa Santra et al.
VACCINE (2009)
Adenovirus serotype 5 hexon mediates liver gene transfer
Simon N. Waddington et al.
CELL (2008)
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Alexandre Harari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Susan P. Buchbinder et al.
LANCET (2008)
EV01:: A phase I trial in healthy HIV negative volunteers to evaluate a clade CHIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
Pierre-Alexandre Bart et al.
VACCINE (2008)
EV02:: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
Sheena McCormack et al.
VACCINE (2008)
Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice
David Cooper et al.
JOURNAL OF VIROLOGY (2008)
Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus Ankara-Human immunodeficiency virus vaccine vectors
Xiugen Zhang et al.
JOURNAL OF VIROLOGY (2007)
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
Peter Abbink et al.
JOURNAL OF VIROLOGY (2007)
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease
Philip M. McKenna et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120 - Negative results fail to trigger a phase 3 correlates trial
Nina D. Russell et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
Elizabeth J. McFarland et al.
AIDS (2006)
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach
GS Tan et al.
VIROLOGY (2005)
A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus
BL Rao et al.
LANCET (2004)
Share Paper
